CJC-1295 no DAC
CJC-1295 no DAC
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. These products are not drugs, foods, or cosmetics, and are not intended to diagnose, treat, cure, or prevent any disease. Purchasers must be 21 years or older. By purchasing, the buyer agrees to use these products in compliance with all applicable laws and regulations.
CJC-1295 No DAC Overview
CJC-1295 No DAC is a modified GHRH(1-29) analog incorporating four amino acid substitutions at positions 2, 8, 15, and 27 designed to confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation while preserving receptor binding affinity. Unlike the DAC-modified version with extended half-life, this variant maintains a shorter duration of action (approximately 30 minutes), enabling amplification of physiologic GH pulse patterns rather than sustained elevation. Research models examine its effects on pituitary GHRH receptor activation, growth hormone secretagogue activity, IGF-1 pathway stimulation, circadian GH rhythm modulation, and metabolic signaling in laboratory settings.
History
CJC-1295 was developed by ConjuChem Biotechnologies in the early 2000s as part of efforts to create GHRH analogs with improved pharmacokinetic properties. The original CJC-1295 with DAC (drug affinity complex) was designed for prolonged activity through albumin binding, reaching phase II experimental programs before discontinuation. The No DAC variant, retaining the core GHRH(1-29) modifications without the albumin-binding complex, emerged as a research tool for studying pulsatile signaling dynamics and has become widely utilized in somatotroph axis investigations.
CJC-1295 no DAC Structure
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3367.9 g/mol
PubChem CID: 91976842
Research Findings
CJC-1295 No DAC has been extensively studied in neuroendocrine research, with investigations focusing on pulsatile signaling patterns, pituitary pathway pharmacology, downstream effects, and somatotroph axis regulation in various experimental models. Studies examine its role in amplifying endogenous pulsatile signaling without disrupting native rhythms.
Key Areas of Research:
- Signaling: Pulsatile, circadian, peak modulation
- Pharmacology: Target binding, somatotroph, cAMP
- Downstream: Hepatic signaling, cascades, activation
- Endocrine: Lipolysis, nitrogen, protein synthesis
Together, these investigations demonstrate CJC-1295 No DAC's ability to modulate pulsatile endocrine signaling patterns. As a short-acting GHRH analog, it provides a research framework for examining hypothalamic-pituitary-somatotroph axis function, pulsatile dynamics, and downstream signaling in diverse experimental paradigms.
References
Jetté, L., et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052–3058.
Teichman, S.L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.
Ionescu, M., & Frohman, L.A. (2006). Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797.